{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:40:24Z","timestamp":1791668424643,"version":"4.3.4"},"reference-count":94,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32071252"],"award-info":[{"award-number":["32071252"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2021-YGJC-01"],"award-info":[{"award-number":["2021-YGJC-01"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2021-YGJC-02"],"award-info":[{"award-number":["2021-YGJC-02"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2021-MS-121"],"award-info":[{"award-number":["2021-MS-121"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation of Liaoning Province of China","award":["32071252"],"award-info":[{"award-number":["32071252"]}]},{"name":"Natural Science Foundation of Liaoning Province of China","award":["2021-YGJC-01"],"award-info":[{"award-number":["2021-YGJC-01"]}]},{"name":"Natural Science Foundation of Liaoning Province of China","award":["2021-YGJC-02"],"award-info":[{"award-number":["2021-YGJC-02"]}]},{"name":"Natural Science Foundation of Liaoning Province of China","award":["2021-MS-121"],"award-info":[{"award-number":["2021-MS-121"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Alzheimer\u2019s disease (AD) urgently needs innovative treatments due to the increasing aging population and lack of effective drugs and therapies. The amyloid fibrosis of AD-associated \u03b2-amyloid (A\u03b2) that could induce a series of cascades, such as oxidative stress and inflammation, is a critical factor in the progression of AD. Recently, peptide-based therapies for AD are expected to be great potential strategies for the high specificity to the targets, low toxicity, fast blood clearance, rapid cell and tissue permeability, and superior biochemical characteristics. Specifically, various chiral amino acids or peptide-modified interfaces draw much attention as effective manners to inhibit A\u03b2 fibrillation. On the other hand, peptide-based inhibitors could be obtained through affinity screening such as phage display or by rational design based on the core sequence of A\u03b2 fibrosis or by computer aided drug design based on the structure of A\u03b2. These peptide-based therapies can inhibit A\u03b2 fibrillation and reduce cytotoxicity induced by A\u03b2 aggregation and some have been shown to relieve cognition in AD model mice and reduce A\u03b2 plaques in mice brains. This review summarizes the design method and characteristics of peptide inhibitors and their effect on the amyloid fibrosis of A\u03b2. We further describe some analysis methods for evaluating the inhibitory effect and point out the challenges in these areas, and possible directions for the design of AD drugs based on peptides, which lay the foundation for the development of new effective drugs in the future.<\/jats:p>","DOI":"10.3390\/ijms241713110","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T07:25:24Z","timestamp":1692775524000},"page":"13110","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Advances in Alzheimer\u2019s Disease-Associated A\u03b2 Therapy Based on Peptide"],"prefix":"10.3390","volume":"24","author":[{"given":"Cunli","family":"Wang","sequence":"first","affiliation":[{"name":"School of Biomedical Engineering, Faculty of Medicine, Dalian University of Technology, Lingshui Road, Dalian 116024, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Shao","sequence":"additional","affiliation":[{"name":"School of Biomedical Engineering, Faculty of Medicine, Dalian University of Technology, Lingshui Road, Dalian 116024, China"},{"name":"Liaoning Key Lab of Integrated Circuit and Biomedical Electronic System, Dalian University of Technology, Dalian 116024, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[{"name":"School of Biomedical Engineering, Faculty of Medicine, Dalian University of Technology, Lingshui Road, Dalian 116024, China"},{"name":"Liaoning Key Lab of Integrated Circuit and Biomedical Electronic System, Dalian University of Technology, Dalian 116024, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyao","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Biomedical Engineering, Faculty of Medicine, Dalian University of Technology, Lingshui Road, Dalian 116024, China"},{"name":"School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin 124221, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5392-8019","authenticated-orcid":false,"given":"Hangyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Biomedical Engineering, Faculty of Medicine, Dalian University of Technology, Lingshui Road, Dalian 116024, China"},{"name":"Liaoning Key Lab of Integrated Circuit and Biomedical Electronic System, Dalian University of Technology, Dalian 116024, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Biomedical Engineering, Faculty of Medicine, Dalian University of Technology, Lingshui Road, Dalian 116024, China"},{"name":"Liaoning Key Lab of Integrated Circuit and Biomedical Electronic System, Dalian University of Technology, Dalian 116024, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Alzheimer\u2019s Association (2023). 2023 Alzheimer\u2019s Disease Facts and Figures. Alzheimer\u2019s Dement., 19, 1598\u20131695.","DOI":"10.1002\/alz.13016"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.37765\/ajmc.2020.88482","article-title":"Economic burden of Alzheimer disease and managed care considerations","volume":"26","author":"Wong","year":"2020","journal-title":"Am. J. Manag. Care"},{"key":"ref_3","unstructured":"Alzheimer\u2019s Disease International (2018). World Alzheimer Report 2018, Alzheimer\u2019s Disease International."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clinbiochem.2019.04.015","article-title":"Clinical aspects of Alzheimer\u2019s disease","volume":"72","year":"2019","journal-title":"Clin. Biochem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1038\/s41380-022-01531-9","article-title":"Dissecting the clinical heterogeneity of early-onset Alzheimer\u2019s disease","volume":"27","author":"Sirkis","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","article-title":"Alzheimer\u2019s disease","volume":"7","author":"Knopman","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ichimata, S., Martinez-Valbuena, I., Lee, S., Li, J., Karakani, A.M., and Kovacs, G.G. (2023). Distinct molecular signatures of amyloid-beta and tau in Alzheimer\u2019s disease associated with down syndrome. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241411596"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fphar.2015.00221","article-title":"\u03b2-Amyloid: The key peptide in the pathogenesis of Alzheimer\u2019s disease","volume":"6","author":"Sun","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40035-020-00195-1","article-title":"Peripheral clearance of brain-derived A\u03b2 in Alzheimer\u2019s disease: Pathophysiology and therapeutic perspectives","volume":"9","author":"Cheng","year":"2020","journal-title":"Transl. Neurodegener."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13195-019-0529-5","article-title":"The \u201crights\u201d of precision drug development for Alzheimer\u2019s disease","volume":"11","author":"Cummings","year":"2019","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrneurol.2012.118","article-title":"Immunotherapy for Alzheimer disease\u2014The challenge of adverse effects","volume":"8","author":"Liu","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0197-4580(98)00052-9","article-title":"Evolution in the conceptualization of dementia and Alzheimer\u2019s disease: Greco-Roman period to the 1960s","volume":"19","author":"Berchtold","year":"1998","journal-title":"Neurobiol. Aging"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s10571-022-01230-7","article-title":"Tau aggregation inhibiting peptides as potential therapeutics for Alzheimer\u2019s disease","volume":"43","author":"Aillaud","year":"2023","journal-title":"Cell Mol. Neurobiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41582-021-00540-6","article-title":"The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA","volume":"17","author":"Karlawish","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12981-016-0101-3","article-title":"Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: A sub-study of the ANRS-138 EASIER trial","volume":"13","author":"Braun","year":"2016","journal-title":"AIDS Res. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.neuropharm.2016.10.016","article-title":"Block of voltage-gated calcium channels by peptide toxins","volume":"127","author":"Bourinet","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/pm\/pny132","article-title":"Intrathecal therapy for chronic pain: A review of morphine and ziconotide as firstline options","volume":"20","author":"Deer","year":"2019","journal-title":"Pain Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40290-018-0261-7","article-title":"Peptide-based therapeutics for oncology","volume":"33","author":"Fisher","year":"2019","journal-title":"Pharm. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/j.pain.0000000000000831","article-title":"The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine","volume":"158","author":"Iyengar","year":"2017","journal-title":"Pain"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/1753-0407.12969","article-title":"Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects","volume":"11","author":"Sloan","year":"2019","journal-title":"J. Diabetes"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/1573399813666170414101450","article-title":"Effect of glucagon-like peptide-1 receptor agonists on all-cause mortality and cardiovascular outcomes: A meta-analysis","volume":"14","author":"Peterson","year":"2018","journal-title":"Curr. Diabetes Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1016\/j.jmb.2018.12.015","article-title":"Peptide design principles for antimicrobial applications","volume":"431","author":"Torres","year":"2019","journal-title":"J. Mol. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Lee, A.C., Harris, J.L., Khanna, K.K., and Hong, J.H. (2019). A comprehensive review on current advances in peptide drug development and design. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20102383"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1021\/acs.jmedchem.7b00318","article-title":"The current state of peptide drug discovery: Back to the future?","volume":"61","author":"Henninot","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Sidorova, A., Bystrov, V., Lutsenko, A., Shpigun, D., Belova, E., and Likhachev, I. (2021). Quantitative assessment of chirality of protein secondary structures and phenylalanine peptide nanotubes. Nanomaterials, 11.","DOI":"10.3390\/nano11123299"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1021\/ja050088m","article-title":"Polypeptide chains containing d-\u03b3-hydroxyvaline","volume":"127","author":"Pisarewicz","year":"2005","journal-title":"J. Am. Chem. Soc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1002\/chir.20039","article-title":"Chiral discrimination between thalidomide enantiomers using a solid surface with two-dimensional chirality","volume":"16","author":"Nakanishi","year":"2004","journal-title":"Chirality"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1468-1331.2009.02697.x","article-title":"Levodopa in the treatment of Parkinson\u2019s disease","volume":"16","author":"Schapira","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1039\/b609047h","article-title":"Designing peptide based nanomaterials","volume":"37","author":"Ulijn","year":"2008","journal-title":"Chem. Soc. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1002\/anie.201510140","article-title":"Inversion of the supramolecular chirality of nanofibrous structures through co-assembly with achiral molecules","volume":"55","author":"Liu","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1039\/b800409a","article-title":"Lost in translation? Chirality effects in the self-assembly of nanostructured gel-phase materials","volume":"38","author":"Smith","year":"2009","journal-title":"Chem. Soc. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"10736","DOI":"10.1021\/ja5049626","article-title":"Chiral effect at protein\/graphene interface: A bioinspired perspective to understand amyloid formation","volume":"136","author":"Qing","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"160696","DOI":"10.1098\/rsos.160696","article-title":"Thioflavin T as an amyloid dye: Fibril quantification, optimal concentration and effect on aggregation","volume":"4","author":"Xue","year":"2017","journal-title":"R. Soc. Open Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3109\/03602532.2014.882354","article-title":"Atomic force microscopy to study molecular mechanisms of amyloid fibril formation and toxicity in Alzheimer\u2019s disease","volume":"46","author":"Drolle","year":"2014","journal-title":"Drug Metab. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"13725","DOI":"10.1039\/C9CC06980A","article-title":"Unravelling the mechanism of amyloid-beta peptide oligomerization and fibrillation at chiral interfaces","volume":"55","author":"Gong","year":"2019","journal-title":"Chem. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1021\/cr960396q","article-title":"Polyoxometalates in medicine","volume":"98","author":"Rhule","year":"1998","journal-title":"Chem. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1002\/ejic.200800759","article-title":"Chirality in polyoxometalate chemistry","volume":"32","author":"Hasenknopf","year":"2008","journal-title":"Eur. J. Inorg. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1021\/jacs.8b12537","article-title":"Chirality-selected chemical modulation of amyloid aggregation","volume":"141","author":"Gao","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1038\/s41467-019-11762-0","article-title":"Inhibition of amyloid beta toxicity in zebrafish with a chaperone-gold nanoparticle dual strategy","volume":"10","author":"Javed","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Liu, P., Chen, G., and Zhang, J. (2022). A review of liposomes as a drug delivery system: Current status of approved products, regulatory environments, and future perspectives. Molecules, 27.","DOI":"10.3390\/molecules27041372"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7369","DOI":"10.1039\/D0SC02212H","article-title":"Molecular chirality mediated amyloid formation on phospholipid surfaces","volume":"11","author":"Wang","year":"2020","journal-title":"Chem. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1038\/s41467-020-18525-2","article-title":"Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer\u2019s disease","volume":"11","author":"Hou","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"116229","DOI":"10.1016\/j.trac.2021.116229","article-title":"Screening of specific binding peptides using phage-display techniques and their biosensing applications","volume":"137","author":"Xu","year":"2021","journal-title":"TrAC Trend Anal. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4161\/mabs.27240","article-title":"Drugs derived from phage display: From candidate identification to clinical practice","volume":"6","author":"Nixon","year":"2014","journal-title":"mAbs"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"21287","DOI":"10.1021\/acsami.5b05606","article-title":"Chromium(III) binding phage screening for the selective adsorption of Cr(III) and chromium speciation","volume":"7","author":"Yang","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.talanta.2017.07.005","article-title":"Screening arsenic(III)-binding peptide for colorimetric detection of arsenic(III) based on the peptide induced aggregation of gold nanoparticles","volume":"177","author":"Yang","year":"2018","journal-title":"Talanta"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Das, S., Devireddy, R., and Gartia, M.R. (2023). Surface plasmon resonance (SPR) sensor for cancer biomarker detection. Biosensors, 13.","DOI":"10.3390\/bios13030396"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1021\/acs.analchem.2c04643","article-title":"DNAzyme-based microscale thermophoresis sensor","volume":"95","author":"Yu","year":"2023","journal-title":"Anal. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"124325","DOI":"10.1016\/j.talanta.2023.124325","article-title":"Quartz crystal microbalance biosensor for the detection of procalcitonin","volume":"257","author":"Pohanka","year":"2023","journal-title":"Talanta"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"11882","DOI":"10.1021\/ja0619861","article-title":"Phage display affords peptides that modulate beta-amyloid aggregation","volume":"128","author":"Orner","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1021\/acschemneuro.1c00035","article-title":"Brain targeting and A\u03b2 binding bifunctional nanoparticles inhibit amyloid protein aggregation in APP\/PS1 transgenic mice","volume":"12","author":"Zhang","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/nprot.2006.116","article-title":"Morris water maze: Procedures for assessing spatial and related forms of learning and memory","volume":"1","author":"Vorhees","year":"2006","journal-title":"Nat. Protoc."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Wang, F., Zhou, X.-L., Yang, Q.-G., Xu, W.-H., Wang, F., Chen, Y.-P., and Chen, G.-H. (2011). A peptide that binds specifically to the \u03b2-amyloid of Alzheimer\u2019s disease: Selection and assessment of anti-\u03b2-amyloid neurotoxic effects. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0027649"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/cbic.200300570","article-title":"Mirror-image phage display: Aiming at the mirror","volume":"4","author":"Wiesehan","year":"2003","journal-title":"ChemBioChem"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1126\/science.271.5257.1854","article-title":"Identification of d-peptide ligands through mirrorimage phage display","volume":"271","author":"Schumacher","year":"1996","journal-title":"Science"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1039\/b904138a","article-title":"Mirror image phage display\u2014A method to generate d-peptide ligands for use in diagnostic or therapeutical applications","volume":"5","author":"Funke","year":"2009","journal-title":"Mol. Biosyst."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1002\/cmdc.200800273","article-title":"Reduction of Alzheimer\u2019s disease amyloid plaque load in transgenic mice by D3, A D-enantiomeric peptide identified by mirror image phage display","volume":"3","author":"Wiesehan","year":"2008","journal-title":"Chem. Med. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1021\/cn100057j","article-title":"Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer\u2019s Disease transgenic mice","volume":"1","author":"Funke","year":"2010","journal-title":"ACS Chem. Neurosci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"13222","DOI":"10.1038\/srep13222","article-title":"QIAD assay for quantitating a compound\u2019s efficacy in elimination of toxic A\u03b2 oligomers","volume":"5","author":"Brener","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1021\/acschemneuro.6b00047","article-title":"Increase of positive net charge and conformational rigidity enhances the efficacy of d-enantiomeric peptides designed to eliminate cytotoxic abeta species","volume":"7","author":"Ziehm","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.bbamem.2016.07.002","article-title":"Blood-brain barrier penetration of an A\u03b2-targeted, arginine-rich, d-enantiomeric peptide","volume":"1858","author":"Jiang","year":"2016","journal-title":"Biochim. Biophys. Acta BBA Biomembr."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"8545","DOI":"10.1074\/jbc.271.15.8545","article-title":"Arrest of beta-amyloid fibril formation by a pentapeptide ligand","volume":"271","author":"Tjernberg","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1021\/acschemneuro.9b00469","article-title":"CLVFFA-functionalized gold nanoclusters inhibit A\u03b240 fibrillation, fibrils\u2019 prolongation, and mature fibrils\u2019 disaggregation","volume":"10","author":"Hao","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1021\/bi701415b","article-title":"Designing peptide inhibitors for oligomerization and toxicity of Alzheimer\u2019s beta-amyloid peptide","volume":"47","author":"Austen","year":"2008","journal-title":"Biochemistry"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1096\/fj.03-1346fje","article-title":"A strategy for designing inhibitors of R-synuclein aggregation and toxicity as a novel treatment for Parkin","volume":"18","author":"Paleologou","year":"2004","journal-title":"FASEB J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1399-3011.2004.00156.x","article-title":"Inhibition of \u03b2-amyloid toxicity by short peptides containing N-methyl amino acids","volume":"63","author":"Cruz","year":"2004","journal-title":"J. Pept. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"34874","DOI":"10.1074\/jbc.M212694200","article-title":"Stereoselective interactions of peptide inhibitors with the \u03b2-amyloid peptide","volume":"278","author":"Chalifour","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"9906","DOI":"10.1021\/bi060837s","article-title":"N-Methylated peptide inhibitors of beta-amyloid aggregation and toxicity. Optimization of the inhibitor structure","volume":"45","author":"Kokkoni","year":"2006","journal-title":"Biochemistry"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1042\/BCJ20200290","article-title":"Rationally designed peptide-based inhibitor of A\u03b242 fibril formation and toxicity: A potential therapeutic strategy for Alzheimer\u2019s disease","volume":"477","author":"Horsley","year":"2020","journal-title":"Biochem. J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"19262","DOI":"10.1038\/s41598-021-98644-y","article-title":"Effects of A\u03b2-derived peptide fragments on fibrillogenesis of A\u03b2","volume":"11","author":"Faisal","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Usmani, S.S., Bedi, S., Samuel, J.S., Singh, S., Kalra, S., Kumar, P., Ahuja, A.A., Sharma, M., Gautam, A., and Raghava, G.P.S. (2017). THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0181748"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cbpa.2017.02.006","article-title":"Cyclic peptide therapeutics: Past, present and future","volume":"38","author":"Zorzi","year":"2017","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"8236","DOI":"10.1002\/anie.201405109","article-title":"Rational design and identification of a non-peptidic aggregation inhibitor of amyloid-beta based on a pharmacophore motif obtained from cyclo[-Lys-Leu-Val-Phe-Phe-]","volume":"53","author":"Arai","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S1047-8477(02)00625-1","article-title":"Assemblies of Alzheimer\u2019s peptides A\u03b225\u201335 and A\u03b231\u201335: Reverse-turn conformation and side-chain interactions revealed by X-ray diffraction","volume":"141","author":"Bond","year":"2003","journal-title":"J. Struct. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/jnr.10859","article-title":"Residues 17\u201320 and 30\u201335 of beta-amyloid play critical roles in aggregation","volume":"75","author":"Liu","year":"2004","journal-title":"J. Neurosci. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0306-4522(98)00727-1","article-title":"Beta-amyloid peptide fragment 31\u201335 induces apoptosis in cultured cortical neurons","volume":"92","author":"Yan","year":"1999","journal-title":"Neuroscience"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bbrc.2004.09.024","article-title":"\u03b2-amyloidderived pentapeptide RIIGLa inhibits A\u03b21\u201342 aggregation and toxicity","volume":"324","author":"Fulop","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"14175","DOI":"10.1073\/pnas.0807163105","article-title":"C-terminal peptides coassemble into A\u03b242 oligomers and protect neurons against A\u03b242-induced neurotoxicity","volume":"105","author":"Fradinger","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nchem.1433","article-title":"Amyloid beta-sheet mimics that antagonize protein aggregation and reduce amyloid toxicity","volume":"4","author":"Cheng","year":"2012","journal-title":"Nat. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/bib\/bbp023","article-title":"Recent advances in computer-aided drug design","volume":"10","author":"Song","year":"2009","journal-title":"Brief Bioinform."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fnmol.2019.00054","article-title":"Structure-based peptide inhibitor design of amyloid-\u03b2 aggregation","volume":"12","author":"Lu","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"ref_82","first-page":"125","article-title":"Synthesis and modification of the amyloid peptide sequence 37\u201342 of A\u03b242 (A\u03b2PP): Efficient synthesis of N-methylated peptides, expanding the tools for peptide research","volume":"60","author":"Escalante","year":"2016","journal-title":"J. Mex. Chem. Soc."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e01681","DOI":"10.7554\/eLife.01681","article-title":"Designed alpha-sheet peptides inhibit amyloid formation by targeting toxic oligomers","volume":"3","author":"Hopping","year":"2014","journal-title":"eLife"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"220261","DOI":"10.1098\/rsob.220261","article-title":"The role of \u03b1-sheet structure in amyloidogenesis: Characterization and implications","volume":"12","author":"Prosswimmer","year":"2022","journal-title":"Open Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41551-021-00819-5","article-title":"Amelioration of Alzheimer\u2019s disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow","volume":"6","author":"Xie","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1902906","DOI":"10.1002\/advs.201902906","article-title":"A novel targeted and high-efficiency nanosystem for combinational therapy for Alzheimer\u2019s disease","volume":"7","author":"Yang","year":"2020","journal-title":"Adv. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1021\/acschemneuro.8b00469","article-title":"Exosomes in Parkinson\u2019s disease: Current perspectives and future challenges","volume":"10","author":"Yuan","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Yoon, J., Lee, S.K., Park, A., Lee, J., Jung, I., Song, K.B., Choi, E.J., Kim, S., and Yu, J. (2023). Exosome from IFN-\u03b3-primed induced pluripotent stem cell-derived mesenchymal stem cells improved skin inflammation and barrier function. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241411635"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Saint-Pol, J., Gosselet, F., Duban-Deweer, S., Pottiez, G., and Karamanos, Y. (2020). Targeting and crossing the blood-brain barrier with extracellular vesicles. Cells, 9.","DOI":"10.3390\/cells9040851"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"eaau6977","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1016\/j.bmc.2018.01.012","article-title":"Peptide chemistry toolbox\u2014Transforming natural peptides into peptide therapeutics","volume":"26","author":"Erak","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.drudis.2016.11.003","article-title":"Peptidomimetic therapeutics: Scientific approaches and opportunities","volume":"22","author":"Qvit","year":"2017","journal-title":"Drug Discov. Today"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.4155\/fmc.15.43","article-title":"Modifying peptides to enhance permeability","volume":"7","author":"Vorherr","year":"2015","journal-title":"Future Med. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ejmech.2014.07.083","article-title":"Lead discovery and optimization strategies for peptide macrocycles","volume":"94","author":"Bhat","year":"2015","journal-title":"Eur. J. Med. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/17\/13110\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:40:46Z","timestamp":1760128846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/17\/13110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":94,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["ijms241713110"],"URL":"https:\/\/doi.org\/10.3390\/ijms241713110","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,23]]}}}